Our Company
About Us
Leadership Team
Board of Directors
Advisory Board
Chemoprotection & ALRN-6924
Overview
Role of P53
Preclinical Research
Scientific Publications
Clinical Development
Investors & Media
Careers
Aileron Presents Proof-of-Concept Clinical Data for ALRN-6924 in Late-Breaking Presentation at EORTC-NCI-AACR Symposium
Transforming the Experience of Chemotherapy for Patients
Learn More
What's New at Aileron
Press Releases
Aileron Therapeutics is a clinical stage company developing a novel medicine, ALRN-6924, to improve the outcomes and the quality of life of cancer patients.
Learn More
ALRN-6924 is administered prior to chemotherapy to protect healthy normal cells from negative side effects.
Learn More
Latest News
May 19, 2021
Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities
May 11, 2021
Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
March 24, 2021
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
More News
